Adcendo will sponsor the Phase Ib clinical trial, and MSD will provide pembrolizumab.

Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcen ...

MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), licensed from China's Kelun-Biotech, ...

US pharma giant Merck & Co, known as MSD outside of the USA and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with Keytruda ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), has demonstrated promise in a Phase II/III study, as the company ...

Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation. The collaboration aims to implement an agentic platform ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, congratulates the Government of Ontario for its recent ...

Ingenia wins KOSDAQ nod, advances MSD-partnered eye drug to global phase 3 Boston-founded biotech aims IPO as MSDs macular ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock ...

The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation.